



TO THE NATIONAL SECURITIES MARKET COMMISSION

Madrid, 2 October, 2023

In compliance with the disclosure duties set out in article 227 of Law 6/2023, of 17 March, on Securities Markets and Investment Services, Laboratorios Farmacéuticos Rovi, S.A. (hereinafter, "**ROVI**" or the "**Company**") informs the National Securities Market Commission as follows:

OTHER RELEVANT INFORMATION

Treasury share transactions under the Liquidity Contract in the third quarter of 2023

In relation to the current liquidity contract signed with Bestinver SV, S.A. in compliance with Circular 1/2017 of 26 April of the National Securities Market Commission on liquidity contracts, amended by Circular 2/2019 of 27 November, we set out below the transactions performed under said liquidity contract in the third quarter of 2023.

- **Securities account balance upon signature of the contract:** 88,495 shares.
- **Initial value of securities account:** 101,750 shares.
- **Purchases:** 100,597 shares.
- **Sales:** 99,426 shares.
- **Average price of purchases:** 40.50 euros.
- **Average price of sales:** 40.44 euros.
- **Final balance of securities account:** 102,921 shares.

- **Cash account balance upon signature of the contract:** 6,000,000.00 euros.
- **Initial balance of cash account:** 5,101,421.23 euros.
- **Cash relating to purchases:** 4,074,283.76 euros.
- **Cash relating to sales:** 4,021,025.70 euros.
- **Trading fees:** 1,212.57 euros.
- **Final balance of cash account:** 5,046,950.60 euros.

The list of transactions performed in the third quarter of 2023 is as follows:

| Purchase/ Sale | Transaction date | No. securities | Block | No. transactions | Average price (€) | Cash (€) | Position at date (No. securities) | Net amount (€) |
|-------------------|---------------------|-------------------|-------|---------------------|-------------------------|---------------|---|-------------------|
| Purchase | 03/07/2023 | 6.510 | NO | 57 | 41,40 | - 269.507,480 | 108.260 | 4.831.913,75 |
| Sale | 03/07/2023 | 6.510 | NO | 49 | 41,39 | 269.417,159 | 101.750 | 5.101.330,91 |
| Purchase | 04/07/2023 | 6.644 | NO | 58 | 41,58 | - 276.261,224 | 108.394 | 4.825.069,69 |
| Sale | 04/07/2023 | 3.963 | NO | 32 | 41,66 | 165.091,619 | 104.431 | 4.990.161,31 |
| Purchase | 05/07/2023 | 6.891 | NO | 58 | 40,99 | - 282.479,538 | 111.322 | 4.707.681,77 |
| Sale | 05/07/2023 | 6.891 | NO | 54 | 41,00 | 282.516,660 | 104.431 | 4.990.198,43 |
| Purchase | 06/07/2023 | 6.911 | NO | 55 | 40,74 | - 281.564,703 | 111.342 | 4.708.633,73 |
| Sale | 06/07/2023 | 6.911 | NO | 59 | 40,75 | 281.610,924 | 104.431 | 4.990.244,65 |
| Purchase | 07/07/2023 | 6.637 | NO | 57 | 40,12 | - 266.301,340 | 111.068 | 4.723.943,31 |
| Sale | 07/07/2023 | 5.165 | NO | 41 | 40,03 | 206.777,360 | 105.903 | 4.930.720,67 |
| Purchase | 10/07/2023 | 6.760 | NO | 57 | 39,01 | - 263.715,320 | 112.663 | 4.667.005,35 |
| Sale | 10/07/2023 | 6.760 | NO | 55 | 38,93 | 263.153,760 | 105.903 | 4.930.159,11 |
| Purchase | 11/07/2023 | 6.996 | NO | 54 | 38,78 | - 271.329,457 | 112.899 | 4.658.829,65 |
| Sale | 11/07/2023 | 6.996 | NO | 70 | 38,84 | 271.725,819 | 105.903 | 4.930.555,47 |
| Purchase | 12/07/2023 | 6.908 | NO | 83 | 38,32 | - 264.701,960 | 112.811 | 4.665.853,51 |
| Sale | 12/07/2023 | 6.683 | NO | 57 | 38,26 | 255.682,440 | 106.128 | 4.921.535,95 |
| Purchase | 13/07/2023 | 5.876 | NO | 55 | 39,04 | - 229.406,079 | 112.004 | 4.692.129,87 |
| Sale | 13/07/2023 | 4.135 | NO | 33 | 39,00 | 161.258,339 | 107.869 | 4.853.388,21 |
| Purchase | 14/07/2023 | 400 | NO | 3 | 39,34 | - 15.736,000 | 108.269 | 4.837.652,21 |
| Sale | 14/07/2023 | 4.783 | NO | 36 | 39,53 | 189.060,939 | 103.486 | 5.026.713,15 |
| Purchase | 17/07/2023 | 5.424 | NO | 52 | 40,13 | - 217.657,900 | 108.910 | 4.809.055,25 |
| Sale | 17/07/2023 | 5.796 | NO | 58 | 39,98 | 231.733,580 | 103.114 | 5.040.788,83 |
| Purchase | 18/07/2023 | 5.000 | NO | 34 | 39,96 | - 199.820,000 | 108.114 | 4.840.968,83 |
| Sale | 18/07/2023 | 5.766 | NO | 49 | 39,98 | 230.515,464 | 102.348 | 5.071.484,29 |
| Purchase | 19/07/2023 | 5.606 | NO | 37 | 41,30 | - 231.555,017 | 107.954 | 4.839.929,27 |
| Sale | 19/07/2023 | 5.606 | NO | 37 | 41,56 | 232.961,139 | 102.348 | 5.072.890,41 |
| Purchase | 20/07/2023 | 5.913 | NO | 50 | 42,13 | - 249.107,865 | 108.261 | 4.823.782,55 |
| Sale | 20/07/2023 | 5.913 | NO | 48 | 42,13 | 249.095,940 | 102.348 | 5.072.878,49 |
| Purchase | 21/07/2023 | 6.060 | NO | 49 | 42,06 | - 254.905,119 | 108.408 | 4.817.973,37 |
| Sale | 21/07/2023 | 5.487 | NO | 42 | 41,95 | 230.180,418 | 102.921 | 5.048.153,79 |
| Purchase | 24/07/2023 | 5.945 | NO | 53 | 41,57 | - 247.134,504 | 108.866 | 4.801.019,29 |
| Sale | 24/07/2023 | 5.945 | NO | 42 | 41,56 | 247.082,960 | 102.921 | 5.048.102,25 |
| Purchase | 25/07/2023 | 6.116 | NO | 49 | 41,38 | - 253.100,257 | 109.037 | 4.795.001,99 |
| Sale | 25/07/2023 | 6.116 | NO | 50 | 41,39 | 253.161,178 | 102.921 | 5.048.163,17 |

| Purchase/ Sale | Transaction date | No. securities | Block | No. transactions | Average price (€) | Cash (€) | Position at date (No. securities) | Net amount (€) |
|---------------------------|-----------------------------|---------------------------|--------------|-----------------------------|----------------------------------|-------------------|--|---------------------------|
| Trading fees | | | | | | | | -1,212.57 |
| TOTAL | | 1,171 | | | | -53,258.06 | 102,921 | 5,046,950.60 |

Mr Juan López-Belmonte Encina
Chairman and Chief Executive Officer
Laboratorios Farmacéuticos Rovi, S.A.